Nashville, TN Clinical Trials Report — July 2026

Nashville participants should act promptly if they match a study closing soon: 50 recruiting trials are expected to close within the next 90 days, including 8 that accept healthy volunteers. Prostate and breast cancer lead the closing-soon conditions with 4 trials each, followed by cardiovascular diseases and autonomic failure with 3 each.

Nashville remains one of Tennessee’s strongest clinical research centers, with 1,307 recruiting trials across 437 facilities. The city opened 20 new studies in July, down from 23 in May. The six-month pattern shows new openings declining from 28 in February to 20 in July, with 6 recorded for August so far.

Closing windows for Nashville patients and volunteers

Enrollment can end before a projected closing date if a study reaches its participant target. People with the following conditions should review eligibility and contact study teams without delay:

• Prostate cancer (4 trials)
• Breast cancer (4 trials)
• Cardiovascular diseases (3 trials)
• Autonomic failure (3 trials)
• Pancreatic cancer (2 trials)
• Supine hypertension (2 trials)
• Advanced malignant neoplasm (2 trials)
• Colorectal cancer (2 trials)
• Metastatic solid tumor (2 trials)
• HER2-negative breast cancer (2 trials)

Eight of the 50 closing-soon studies accept healthy volunteers. Nashville has 75 healthy-volunteer trials recruiting overall, but only 1 of July’s 20 new trials accepts healthy participants. Healthy volunteers should confirm age, medication, medical-history, and time-commitment requirements early because these studies may fill quickly.

Major new Phase 3 opportunities

July’s new-trial mix includes 12 drug studies, 7 categorized as other, 2 behavioral studies, and 2 biological studies. Several large late-stage trials from major sponsors provide notable opportunities for Nashville patients:

• AstraZeneca is sponsoring NCT07720284, a Phase 3 study comparing Dato-DXd plus rilvegostomig with standard care for adults with high-risk muscle-invasive urothelial cancer after surgery. The study plans to enroll 915 participants.
• Akeso is leading NCT07700979, a Phase 3 study of cadonilimab plus chemotherapy for previously untreated, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. Planned enrollment is 900 participants.
• AbbVie sponsors NCT07728188, a Phase 3 study comparing injected etentamig plus oral pomalidomide with standard therapies for adults with relapsed or refractory multiple myeloma. The study expects 520 participants.
• Vanderbilt University Medical Center sponsors NCT07685977, the ARTEMIS study of robotic bronchoscopy and rapid onsite evaluation. This randomized study plans to enroll 400 participants and will examine whether rapid evaluation improves diagnostic performance.
• Bristol-Myers Squibb sponsors NCT07689006, a real-world observational study of treatment outcomes in relapsed or refractory multiple myeloma. It plans to include 341 participants.
• TScan Therapeutics sponsors NCT07702578, a Phase 3 study of T-cell receptor-engineered donor T cells following allogeneic stem cell transplantation. Planned enrollment is 310 participants.

New condition activity is concentrated in relapsed or refractory multiple myeloma, with 2 new trials. Acute myeloid leukemia, gallbladder cancer, biliary tract cancer, cholangiocarcinoma, colorectal cancer, and several cochlear-implant categories each appear in one new study. Vanderbilt University Medical Center sponsors 5 of the month’s openings, while AstraZeneca and Bristol-Myers Squibb sponsor 2 each. Overall, 11 new studies are industry-sponsored and 8 are categorized as other.

Where Nashville has the most research activity

Vanderbilt University Medical Center is Nashville’s leading access point, with 326 recruiting trials. Its broad academic and hospital research network spans cancer, cardiovascular disease, neurology, children’s health, devices, diagnostics, and other specialties. Cancer-focused sites also account for a substantial share of local activity.

• Vanderbilt University Medical Center (326 trials)
• SCRI Oncology Partners (119 trials)
• Vanderbilt University/Ingram Cancer Center (95 trials)
• Sarah Cannon Research Institute (68 trials)
• Tennessee Oncology (55 trials)
• Vanderbilt University (50 trials)
• Research Site (47 trials)
• Vanderbilt-Ingram Cancer Center (38 trials)
• The Children's Hospital at TriStar Centennial (28 trials)
• Vanderbilt Breast Center at One Hundred Oaks (16 trials)
• Tennessee Oncology, PLLC (13 trials)
• Monroe Carell Jr. Children's Hospital at Vanderbilt (12 trials)

Patients seeking oncology studies should start with Vanderbilt-Ingram-affiliated locations, SCRI Oncology Partners, Sarah Cannon Research Institute, and Tennessee Oncology. Families can also check The Children's Hospital at TriStar Centennial and Monroe Carell Jr. Children's Hospital at Vanderbilt, especially since 3 July openings include children.

Eligibility and options beyond Nashville

Of July’s new studies, 20 include older adults, 3 include children, and 1 is male-only. No new study is female-only. Eligibility remains study-specific, so patients should ask about age ranges, prior treatments, disease stage, medications, travel requirements, and screening procedures before arranging a visit.

People willing to travel can also search other Tennessee research markets. Memphis has 7 recruiting trials, Knoxville has 2, and Germantown and Jackson have 1 each. These locations may provide alternatives when a Nashville study has closed enrollment or does not match a participant’s treatment history.

As July’s opening count falls below earlier 2026 levels, the active Nashville pipeline remains large. Patients with cancer, cardiovascular conditions, autonomic failure, or other listed conditions—and healthy volunteers considering research—should monitor local listings now as enrollment opportunities change through the rest of the summer.